[Futraful and UFT, their metabolic characteristics].
Investigations were made in human on the metabolism of Futraful (FT) and UFT (combination of uracil and FT), both of which are anticancer agents of pyrimidine metabolism antagonist. As a result, it was demonstrated that from the metabolic view point, those drugs essentially have a tumor-selective toxicity. Next, the mechanism of the superior clinical anticancer effect of UFT, compared to FT, was investigated enzymatically, showing the inhibitory effect of uracil on the degradation of 5-fluorouracil generated from FT in the organs and tumor tissues. Discussions were also made for the further development of fluoropyrimidines.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000378:metabolism*; D006801:Humans; D008168:Lung / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005641:Tegafur / Q000378:metabolism*; D014498:Uracil / Q000378:metabolism
D011743:Pyrimidines; D005641:Tegafur; D014498:Uracil; C030986:pyrimidine